Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from BioNTech

Pfizer, Moderna, BioNTech Stocks Tumble After Report Of Plan To Link COVID Vaccines To Child Deaths

Shares of COVID-19 vaccine makers Pfizer Inc (NYSE:PFE), BioNTech SE ADR (NASDAQ:BNTX) and Moderna Inc (NASDAQ:MRNA) are trading lower Friday following a Washington Post report that Trump administration health officials intend to link the vaccines to 25 child deaths. This assertion is reportedly based on unverified submissions to the Vaccine…

Benzinga

Shots Fired! After RFK Jr.'s Senate Grilling, Will Pfizer, Moderna Survive The Battle In D.C.?

It's unprecedented times for the Covid vaccine market, experts say. And Pfizer and Moderna remain under significant pressure.

Investors Business Daily

BioNTech Surges 9% On Promising Test Results For Its Cancer Smart Bomb

BioNTech stock surged Friday after its experimental breast cancer treatment met a prespecified bar for success in a pivotal study.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

RFK Jr. Makes Good On Promise To End Covid Vaccine Mandate. BioNTech Tumbles.

BioNTech stock skidded Wednesday after the Food and Drug Administration ended its broad authorization of Covid vaccines in the U.S.

Investors Business Daily

FTSE 100 edges down despite hopes of end to Russia-Ukraine war

Evening Standard

GSK to be paid up to £370 million after patent row settles in US

CureVac – a German pharmaceutical company – settled a long-running patent dispute with rival BioNTech and Pfizer in the US on Thursday.

Evening Standard

‘Game-changing’ cancer vaccine trial to begin on NHS

The jab uses mRNA technology to train the immune system to fight cancerous cells

The Independent UK

Read news from The Economist, FT, and more,
with one subscription

Patients to be fast-tracked on to new head and neck cancer vaccine trial

The jab uses mRNA technology to train the immune system to fight cancer.

Evening Standard

BioNTech Narrows Losses, Q2 Revenue Doubles As Vaccine Collaboration Drives Growth

BioNTech SE (NASDAQ:BNTX) reported a second-quarter per-share loss of $1.82 (1.60 euros) on Monday, up from a loss of 3.36 euros reported a year ago, compared to beating the consensus loss of $2.42 per share.

Benzinga

Why Is AbbVie Stock Trading Higher On Thursday?

IGI Therapeutics SA, a wholly owned subsidiary of New York-based Ichnos Glenmark Innovation Inc., and AbbVie Inc. (NYSE:ABBV), on Thursday, announced an exclusive licensing agreement for IGI’s lead investigational asset, ISB 2001, developed using IGI’s proprietary BEAT protein platform, for oncology and autoimmune diseases.

Benzinga

Is BioNTech Stock a Buy on Major $11 Billion Cancer-Drug Deal?

With BioNTech sealing a blockbuster $11 billion cancer deal with Bristol-Myers Squibb, should investors be loading up on this rising biotech star?

Barchart

Dow Jones Falls On U.S.-China Tensions, Economic Data; Nucor Jumps As Tesla, Palantir Slide

The Dow Jones fell modestly Monday amid U.S.-China tensions. Palantir and Tesla moved near buy points. Nucor jumped on Trump tariffs.

Investors Business Daily

The FDA Is Limiting Covid Shots. But Moderna, Vaccine Stocks Jumped.

The FDA said Tuesday it will limit future Covid vaccines to older and at-risk Americans. The move buoyed Moderna, BioNTech and Novavax.

Investors Business Daily

Vaccine maker’s £1bn UK investment to create ‘hundreds of high-skilled jobs’

BioNTech developed mRNA vaccines, and cancer immunotherapies notably used to tackle Covid-19.

Evening Standard

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

BioNTech Surges On Summit's Coattails. But Can They Take On Merck?

BioNTech stock rocketed Wednesday after rival Summit Therapeutics unveiled promising results for a novel approach to lung cancer treatment.

Investors Business Daily

Why Moderna Stock Has Surged 15% This Week Despite Mixed News

Moderna stock has surged more than 20% this week after regulatory filings showed several executives bought shares on the open market.

Investors Business Daily

Moderna, BioNTech, Novavax Surge After CDC Reports Two-Week Covid Spike

Moderna stock surged Tuesday after the Centers for Disease Control and Prevention noted a two-week spike in positive Covid tests.

Investors Business Daily

Pfizer Sets Up For A Wild Ride In 2025 Amid Looming Threats From Starboard, Kennedy

Pfizer stock is setting up for a wild ride in 2025 as it faces off with an activist and Robert F. Kennedy Jr. as the possible HHS lead.

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Why Is BioNTech Stock Trading Higher On Friday?

BNT324/DB-1311 trial data show significant antitumor activity in various cancers, with high response rates in small cell lung and prostate cancer patients.

The Guardian - UK

US inflation rises to 2.6% in October; Post Office closures put 2,000 jobs at risk – as it happened

Inflation figures closely watched by US Federal Reserve; core inflation holds steady at 3.3%

Investors Business Daily

BioNTech Nears A Sell Signal After Cutting Outlook Despite Massive Sales Beat

BioNTech stock reversed lower Monday after the company cut its outlook for the year, despite walloping sales estimates.

Investors Business Daily

As Stock Market Awaits Election, Palantir, S&P 500 Nuke Leaders Report

Amid the election, and a Fed rate vote, earnings season roars ahead.

Investors Business Daily

How BioNTech, Up 26% Over Four Days, Is Riding Summit's Coattails To A Recovery

BioNTech stock has climbed 26% over four days as the German biotech rides a round of cancer treatment success from Summit Therapeutics.

Al Jazeera

Mpox crisis: Why do African countries struggle to make or buy vaccines?

African countries produce less than 2 percent of the vaccines the continent needs, experts say.

The Guardian - UK

World-first lung cancer vaccine trials launched across seven countries

First patient in UK gets dose of jab designed to kill most common form of lung cancer – and stop it coming back

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations